Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9729165 | 1.00 | NOS1 (0.50) | NOS1KCNH2SMN1; SMN2ALDH1A1GABRA5 | |
| SCHEMBL14643881 | 1.00 | NOS1 (0.50) | NOS1KCNH2SMN1; SMN2ALDH1A1GABRA5 | |
| SCHEMBL11588307 | 1.00 | NOS1 (0.50) | NOS1KCNH2SMN1; SMN2ALDH1A1GABRA5 | |
| SCHEMBL44477 | 0.98 | NOS1 (0.51) | NOS1KCNH2SMN1; SMN2ALDH1A1GABRA5 | |
| Ammonia Solution, Strong SCHEMBL28007740 | 0.96 | NOS1 (0.50) | NOS1KCNH2SMN1; SMN2ALDH1A1GABRA5 | |
| SCHEMBL2373929 | 0.92 | NOS1 (0.53) | NOS1SMN1; SMN2ALDH1A1GABRA5GABRB2 | |
| Acetamide SCHEMBL9942181 | 0.89 | GABRA5 (0.50) | NOS1KCNH2SMN1; SMN2ALDH1A1GABRA5 | |
| SCHEMBL5911714 | 0.84 | — | — | |
| Pyridine SCHEMBL27812107 | 0.82 | NOS1 (0.51) | NOS1KCNH2SMN1; SMN2ALDH1A1GABRA5 | |
| SCHEMBL8937107 | 0.81 | KCNH2 (0.52) | KCNH2ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107586282-A | A kind of method of the visible optical drive synthesis aminothiazole of 4 alkyl or aryl 2 | 兰州大学 | 2018-01-16 | — | — | CN | disclosed |
| US-8940856-B2 | Heterocyclic compound and heterocyclic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20140100352-A1 | HETEROCYCLIC COMPOUND AND HETEROCYCLIC POLYMERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-04-10 | — | — | US | disclosed |
| CN-101627022-A | Heterocyclic compound and heterocyclic polymer | SUMITOMO CHEMICAL CO | 2010-01-13 | — | — | CN | disclosed |
| US-20090318651-A1 | HETEROCYCLIC COMPOUND AND HETEROCYCLIC POLYMERS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2128146-A1 | HETEROCYCLIC COMPOUNDS AND HETEROCYCLIC POLYMERS | Sumitomo Chemical Company, Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-5162360-A | Treating hypercholesterolemia and atherosclerosis; ACAT acyl-coenzyme A:-cholesterol acyltransferase | WARNER-LAMBERT COMPANY (US) | 1992-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318651-A1 | HETEROCYCLIC COMPOUND AND HETEROCYCLIC POLYMERS | H1-3, H1-2, H1-5 | NOS1 1256/4885KCNH2 119/4885SMN1; SMN2 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.